Influenza [strain A/H5N1] vaccine is under clinical development by BlueWillow Biologics and currently in Phase I for Influenza A Virus, H5N1 Subtype Infections. According to GlobalData, Phase I drugs for Influenza A Virus, H5N1 Subtype Infections have a 55% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Influenza [strain A/H5N1] vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Influenza [strain A/H5N1] vaccine overview
Vaccine candidate was under development for the prophylaxis of pandemic H5N1 influenza virus infections. It is administered by intranasal and intramuscular route and is formulated as oil-in-water nanoemulsion (NE). It is a mucosal vaccine consisting of recombinant H5N1 pandemic flu antigen combined with the nanoemulsion vaccine adjuvant and is based on the NanoStat technology.
BlueWillow Biologics overview
BlueWillow Biologics (BlueWillow) formerly NanoBio is a biopharmaceutical company that develops intranasal and intramuscular vaccines for the prevention and treatment of infectious diseases. The company’s pipeline products include anthrax, H5 influenza, pertussis, RSV, HSV-2, Anthrax, SARS Cov-2 and seasonal influenza. It also develops products based on the proprietary NanoStat development platform that facilitates the development of topical anti-infective products and an array of mucosal vaccines. BlueWillow carries out research and development operations for the development of drugs and vaccines for dermatological conditions, infectious disease, and other therapeutic indications. The company operates through its laboratory located in Michigan, the US. BlueWillow is headquartered in Ann Arbor, Michigan, the US.
For a complete picture of Influenza [strain A/H5N1] vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
